Why Is Everyone Talking About Ozempic? | Found CEO Sarah Jones Simmer
Nov 13, 2023
auto_awesome
The CEO of Found, the largest medically-supported weight care clinic in the country, discusses the failures of the weight loss industry, the rise of GLP1 medications for weight loss, responsible prescribing, and the potential of telehealth in obesity treatment.
Obesity needs to be treated as a chronic condition with a personalized, multifactorial approach rather than focusing on vanity and personal failing.
GLP-1 medications like Semaglutide have shown significant results in treating obesity, but responsible prescribing by qualified healthcare professionals is essential.
Deep dives
Obesity as a Disease
Obesity is a significant public health problem that affects close to 70% of Americans. It should be treated as a chronic condition rather than a personal failing. The traditional approach of simply telling people to eat less and exercise more has been ineffective. Obesity has multiple root causes, such as brain hunger and metabolic factors. The weight loss industry has often treated obesity as a vanity issue rather than focusing on health. To address obesity successfully, a multifactorial and personalized approach is needed.
Challenges in the Treatment of Obesity
The weight loss industry has failed to tackle obesity effectively, resulting in worsening rates of obesity and related complications. The healthcare system, including primary care physicians (PCPs) and cardiologists, lacks training and resources to address obesity comprehensively. Stigma around obesity further hinders access to quality care. PCPs often lack the capacity and knowledge to provide ongoing support for behavior change. The rise of processed foods and environmental factors has also contributed to obesity. To address these challenges, a shift is needed towards treating obesity as a health condition and providing comprehensive, personalized care.
The Role of GLP1 Medications
GLP1 medications, such as Semaglutide, have shown promise in treating obesity. They have been FDA approved for weight loss and have demonstrated significant results in clinical trials. GLP1 medications can lead to bodyweight loss of up to 15% and significant improvements in conditions like hypertension and prediabetes. However, these medications are not intended for recreational use or for those seeking minor weight loss. They should be prescribed responsibly by qualified healthcare professionals who understand the various root causes of obesity and employ a wide toolkit for treatment.
The Importance of Responsible Prescribing and Telehealth
Responsible prescribing is crucial when it comes to GLP1 medications and obesity treatment in general. Prescribing should be done by healthcare professionals who understand the potential risks and benefits of these medications and can assess the individual needs of patients. Telehealth plays an important role in addressing access barriers and reducing stigma around obesity treatment. However, telehealth should be used in conjunction with in-person care, focusing on redistributing resources within the healthcare system. The goal is to provide convenient and efficient care for the majority of individuals struggling with obesity while reserving in-person care for more complex cases.
More than 40% of Americans have obesity, a number that continues to rise. And despite being a multi-billion dollar business — the weight loss industry just isn’t helping people lose weight. Perhaps that’s why new GLP-1 medications are getting so much attention.
To learn more, I spoke to Sarah Jones Simmer, CEO of Found. With over $130M in venture funding, Found is the largest medically-supported weight care clinic in the country.
Join us as we delve into the history of the weight loss industry, and discuss how telehealth (and responsible prescribing) along with new medications, may just be an inflection point.